Company has clocked robust revenue and record growth in profitability during Q2 FY 18, demonstrates the successful outcome of strategies that company embarked upon few years back. On business front, Alivira now contributes to over 65% of the consolidated revenues. Geographically, Europe has contributed to more than 50% of the Alivira business and with the recent US FDA approval for Vizag facility, company expect the US business to ramp up exponentially & also gaining sustainable traction in our Brazilian and Turkish business.
So, taking these into consideration, Low debt equity ratio and 57 % promoter stake, the share can move to a level of about Rs 130 in next one year. Therefore, we recommend to BUY.